Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. The company also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, it offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, a surgical blood salvage system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; OrthoPAT, a perioperative autotranfusion system for orthopedic procedures; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. Haemonetics Corporation was founded in 1971 and is headquartered in Braintree, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNYSE:HAE
CUSIP40502410
Phone781-848-7100
Debt
Debt-to-Equity Ratio0.49
Current Ratio2.84
Quick Ratio1.94
Price-To-Earnings
Trailing P/E Ratio55.02
Forward P/E Ratio45.56
P/E Growth4.38
Sales & Book Value
Annual Sales$903.92 million
Price / Sales5.94
Cash Flow$3.6889 per share
Price / Cash28.16
Book Value$14.08 per share
Price / Book7.38
Profitability
EPS (Most Recent Fiscal Year)$1.87
Net Income$45.57 million
Net Margins2.45%
Return on Equity15.00%
Return on Assets9.04%
Miscellaneous
Employees3,136
Outstanding Shares51,690,000
Market Cap$5.16 billion
Haemonetics (NYSE:HAE) Frequently Asked Questions
What is Haemonetics' stock symbol?
Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."
How will Haemonetics' stock buyback program work?
Haemonetics announced that its Board of Directors has authorized a share buyback plan on Tuesday, February 6th 2018, which permits the company to repurchase $260,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to repurchase shares of its stock through open market purchases. Stock repurchase plans are often a sign that the company's management believes its shares are undervalued.
How were Haemonetics' earnings last quarter?
Haemonetics Co. (NYSE:HAE) posted its quarterly earnings data on Tuesday, August, 7th. The medical instruments supplier reported $0.59 EPS for the quarter, topping analysts' consensus estimates of $0.42 by $0.17. The medical instruments supplier had revenue of $229.35 million for the quarter, compared to the consensus estimate of $219.52 million. Haemonetics had a net margin of 2.45% and a return on equity of 15.00%. View Haemonetics' Earnings History.
When is Haemonetics' next earnings date?
What guidance has Haemonetics issued on next quarter's earnings?
Haemonetics issued an update on its FY19 earnings guidance on Tuesday, August, 7th. The company provided earnings per share (EPS) guidance of $2.00 to $2.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.17. The company issued revenue guidance of $931.04 million to $949.12 million, compared to the consensus revenue estimate of $944.25 million.
What price target have analysts set for HAE?
6 equities research analysts have issued twelve-month price targets for Haemonetics' shares. Their forecasts range from $50.00 to $125.00. On average, they expect Haemonetics' stock price to reach $97.00 in the next twelve months. This suggests that the stock has a possible downside of 6.6%. View Analyst Price Targets for Haemonetics.
What is the consensus analysts' recommendation for Haemonetics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Haemonetics.
What are Wall Street analysts saying about Haemonetics stock?
Here are some recent quotes from research analysts about Haemonetics stock:
- 1. Barrington Research analysts commented, "We think a solid Q2 would likely result in raised FY/19 numbers." (8/9/2018)
- 2. According to Zacks Investment Research, "Haemonetics has been gaining on continued momentum in new business generation and geographical expansion. We are upbeat about Haemonetics’ consistent growth in the Plasma franchise. Strong end-market demand for plasma-derived biopharmaceuticals continues to drive growth. We are also upbeat about the company receiving 510(k) clearance from the FDA for enhancement of its NexSys PCS embedded software which is equipped with the YES technology. The company’s strong cash position boosts investors’ confidence. The expansion in gross margin buoys optimism. Over the past three months, Haemonetics has been outperforming its industry. However, we are disappointed with the fact that despite encouraging growth at the Plasma and Hospitals segments, the company’s sluggish Blood Center business moderated overall growth in the reporting cycle." (6/12/2018)
- 3. Morgan Stanley analysts commented, "We are maintaining our Outperform rating for REGENXBIO. Today, after market close, the company reported 1Q18 results and provided an update on its pipeline. Key takeaways include: 1) all programs remain on track, with topline data from both the wet AMD and HoFH trials expected in late 2018; and 2) the two MPS programs are slated to dose the first patients in mid-2018. With two wholly owned assets poised to deliver clinical data in late 2018, a powerful AAV technology platform with >20+ partnered programs (10 of which are in the clinic), and a cash position of $336 million pro forma, we continue to recommend REGENXBIO shares to risk-tolerant investors." (5/9/2018)
Are investors shorting Haemonetics?
Haemonetics saw a increase in short interest in the month of July. As of July 13th, there was short interest totalling 1,010,817 shares, an increase of 39.0% from the June 29th total of 727,018 shares. Based on an average trading volume of 547,939 shares, the short-interest ratio is presently 1.8 days. Approximately 2.0% of the company's shares are sold short. View Haemonetics' Current Options Chain.
Who are some of Haemonetics' key competitors?
Some companies that are related to Haemonetics include ABIOMED (ABMD), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hill-Rom (HRC), ICU Medical (ICUI), Integra Lifesciences (IART), Globus Medical (GMED), Insulet (PODD), Penumbra (PEN), Cantel Medical (CMD), Novocure (NVCR), NuVasive (NUVA), Merit Medical Systems (MMSI) and Irhythm Technologies (IRTC).
Who are Haemonetics' key executives?
Haemonetics' management team includes the folowing people:
- Mr. Christopher Simon, CEO, Pres & Director (Age 54)
- Mr. William P. Burke, CFO & Exec. VP
- Ms. Michelle L. Basil, EVP, Gen. Counsel & Sec.
- Ms. Jacqueline Scanlan, Sr. VP of Global HR
- Mr. Dan Goldstein, Principal Accounting Officer, VP & Corp. Controller (Age 41)
Has Haemonetics been receiving favorable news coverage?
Media stories about HAE stock have been trending somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Haemonetics earned a media and rumor sentiment score of 0.11 on Accern's scale. They also gave headlines about the medical instruments supplier an impact score of 45.59 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future. View Recent Headlines for Haemonetics.
Who are Haemonetics' major shareholders?
Haemonetics' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (11.51%), Renaissance Technologies LLC (3.81%), Dimensional Fund Advisors LP (2.76%), Wells Fargo & Company MN (2.08%), Acadian Asset Management LLC (1.70%) and Bank of New York Mellon Corp (1.50%). Company insiders that own Haemonetics stock include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Mark W Kroll, Michelle L Basil, Pedro P Granadillo, Ronald G Gelbman, Ronald Merriman, Susan Bartlett Foote, Willaim P Burke and William P Mr Burke. View Institutional Ownership Trends for Haemonetics.
Which institutional investors are selling Haemonetics stock?
HAE stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Millennium Management LLC, BlackRock Inc., Wells Fargo & Company MN, Anchor Capital Advisors LLC, Bank of America Corp DE, Dimensional Fund Advisors LP and Macquarie Group Ltd.. Company insiders that have sold Haemonetics company stock in the last year include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Mark W Kroll, Michelle L Basil, Pedro P Granadillo, Ronald G Gelbman, Susan Bartlett Foote, Willaim P Burke and William P Mr Burke. View Insider Buying and Selling for Haemonetics.
Which institutional investors are buying Haemonetics stock?
HAE stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Robeco Institutional Asset Management B.V., Acadian Asset Management LLC, American Century Companies Inc., BlueMountain Capital Management LLC, Bank of New York Mellon Corp, Sei Investments Co. and American International Group Inc.. View Insider Buying and Selling for Haemonetics.
How do I buy shares of Haemonetics?
Shares of HAE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Haemonetics' stock price today?
One share of HAE stock can currently be purchased for approximately $103.88.
How big of a company is Haemonetics?
Haemonetics has a market capitalization of $5.16 billion and generates $903.92 million in revenue each year. The medical instruments supplier earns $45.57 million in net income (profit) each year or $1.87 on an earnings per share basis. Haemonetics employs 3,136 workers across the globe.
How can I contact Haemonetics?
Haemonetics' mailing address is 400 WOOD RD, BRAINTREE MA, 02184. The medical instruments supplier can be reached via phone at 781-848-7100 or via email at [email protected]
MarketBeat Community Rating for Haemonetics (NYSE HAE)
MarketBeat's community ratings are surveys of what our community members think about Haemonetics and other stocks. Vote "Outperform" if you believe HAE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HAE will underperform the S&P 500 over the long term. You may vote once every thirty days.
